Premium
TNF Impairs In Vivo and In Vitro Natural Killer (NK) Susceptibility of B16 Melanoma Cells
Author(s) -
PALMIERI G.,
MORRONE S.,
LOLLINI P.L.,
GIOVANNI C.,
NICOLETTI G.,
NANNI P.,
FRATI L.,
SANTONI A.
Publication year - 1992
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.1992.tb02860.x
Subject(s) - tumor necrosis factor alpha , in vivo , melanoma , in vitro , immunology , cancer research , cytokine , interferon , biology , mhc class i , major histocompatibility complex , antigen , biochemistry , microbiology and biotechnology
Tumour necrosis factor α (TNF) is a multipotent cytokine which affects many biological properties of both normal and neoplastic cells. Here we show that treatment with TNF reduces B16‐A melanoma cell susceptibility to normal and in vivo‐ and in vitro‐activated NK cell‐mediated killing. This resistance is associated with an enhancement of B16‐A metastatic potential in normal syngeneic mice, but not in anti‐asialo GM1‐treated animals, further supporting the NK dependence of TNF‐induced enhancement of metastatic ability. A significant increase of MHC class I expression on B16‐A murine melanoma cells is observed after TNF treatment. In all these effects TNF interacts positively with interferon γ (IFN γ). Taken together, these results indicate that TNF treatment negatively affects the susceptibility of B16‐A murine melanoma to NK effectors in vivo and in vitro. This decreased susceptibility may be related, at least in part, to enhanced expression of MHC class I antigens on tumour cells.